Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients: prevalence of variants with decreased activity and chemotherapy outcomes.

Abstract excerpt

BACKGROUND: Fluoropyrimidines are among the most useful drugs in oncology with an established record of efficacy and safety. A minority of oncology patients bear genetic variants with reduced activity of the main enzyme catabolizing these drugs, dihydropyrimidine dehydrogenase (DPYD) and may be prone to severe or even lethal adverse effects. PATIENTS AND METHODS: We reviewed the records of gastrointestinal and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antimetabolites, Antineoplastic
• Share to Breast Neoplasms